We validated the ability of hPSC-derived macrophages to efflux cholesterol after a 23-to 28-day differentiation protocol © 2015 American Heart Association, Inc. Objective-To create isogenic human pluripotent stem cell-derived macrophages with and without ABCA1 expression as a model for reverse cholesterol transport. Approach and Results-The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) genome-editing system was used to introduce frameshift mutations into the coding sequence of ATP-binding cassette, subfamily A, member 1. Individual human pluripotent stem cell clones with deleterious mutations were identified, expanded, and differentiated into mature macrophages with a cytokine-based, feeder-free differentiation protocol. Wildtype cells demonstrated effective cholesterol efflux to apoAI acceptor, whereas ABCA1 −/− cells displayed significantly reduced efflux ability and increased expression of proinflammatory cytokines. Conclusions-Human pluripotent stem cell-derived macrophages capable of reverse cholesterol transport can be rapidly generated and genetically edited with CRISPR/Cas9. Introduction of homozygous frameshift mutations results in loss of ABCA1 expression in differentiated macrophages and subsequent reduction of cholesterol efflux capability. This facile genome-editing approach and differentiation protocol pave the way for future studies of the molecular determinants of reverse cholesterol transport and other macrophage properties. (Arterioscler Thromb Vasc Biol. 2016;36:15-18.
T he process by which peripheral cholesterol is returned to the liver for excretion in bile is termed reverse cholesterol transport (RCT). This multistep pathway is necessary for cells to balance cholesterol intake and de novo synthesis against the toxic effects of excess unesterified cholesterol accumulation. The efflux of cholesterol to extracellular acceptors occurs throughout the body; however, the link with atherosclerosis is hypothesized to be exclusively through macrophage RCT. 1 In atherosclerotic lesions, the macrophage is the primary cell type overloaded with cholesterol, and recent epidemiological studies have linked in vitro macrophage cholesterol efflux capacity with risk of adverse cardiovascular events. 2, 3 See accompanying editorial on page 2
The major cellular mediator of cholesterol efflux is ATPbinding cassette, subfamily A, member 1 (ABCA1), which functions as a cell surface transporter. 4 It is required for normal lipidation of lipid-poor apoAI, which is rapidly catabolized in its absence. Lack of ABCA1 is the molecular basis for Tangier disease, an autosomal recessive disease characterized by undetectable high-density lipoprotein-cholesterol levels and cholesterol accumulation in peripheral macrophages. 5 Other molecular mediators of RCT have been identified in mouse knockout models, including the ATP-binding cassette, subfamily G, member 1 6 and scavenger receptor class B, type I 7 pathways, but macrophage RCT requires further study for a full understanding of its determinants. A recent report made use of induced pluripotent stem cells (iPSCs) generated from individuals with Tangier disease and, after differentiation into macrophages, assessed them with respect to cholesterol efflux and inflammatory response to lipopolysaccharide. 8 However, the ability to recruit patients with rare mutations for generation of these cells remains difficult. Here, we demonstrate that genome editing and a simplified differentiation protocol can be used in human PSCs (hPSCs) to generate isogenic macrophage cell lines to test the molecular determinants of macrophage RCT.
adapted from previously published protocols ( Figure 1A ). 9, 10 Monocytes floating in the culture medium were generated by day 15 and could be harvested every 4 to 5 days ≈3 months. After further maturation with macrophage colony-stimulating factor for 5 days, the cells expressed the macrophage-specific cell surface markers CD14, CD68, and CD163 ( Figure 1B ; Figure I in the online-only Data Supplement). These differentiated macrophages retained phagocytic function in a fluorescence-labeled bioparticle assay ( Figure II in the online-only Data Supplement) and effluxed cholesterol in an in vitro RCT assay with apoAI as the cholesterol acceptor ( Figure 1C ).
Genome Editing of ABCA1 With CRISPR/Cas9
To use the clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (Cas9) genome-editing system to knockout the ABCA1 gene, we designed a guide RNA to pair with Cas9 nuclease to target the fourth exon of ABCA1 (Figure 2A ) in the hPSC line HUES 9. Cas9 nuclease was transiently expressed on electroporation of dissociated single cells. The nuclease generated double-strand breaks at this specific site, and subclones were screened for evidence of frameshift insertions or deletions 10 days after transfection. There were 146 clones with at least 1 edited allele from a total of 192 screened clones (76% efficiency). Two unaltered, wild-type clones (C10 and C11) and 2 clones with indels at the predicted Cas9 cleavage site in both alleles (H11 and D6) were chosen for expansion and differentiation into macrophages. The frameshift indel mutations were a homozygous single base insertion in clone H11 and a pair of deletions (2 and 7 bp) in the compound heterozygous clone D6. Sites of possible off-target nuclease activity were identified using 2 independent prediction methods, and we tested a total of 14 sites considered most likely to be off-target sites, based on DNA-RNA mismatches or bulges, in each of the hPSC lines (C10, C11, H11, and D6; sites tested and primer sequences are available in the online-only Data Supplement). No offtarget mutations at these sites were observed. We additionally note that previous whole-genome sequencing studies of CRISPR/Cas9-targeted hPSC lines have documented that off-target mutations are exceedingly rare. 11, 12 To minimize the possibility of confounding by an off-target mutation in a single clone, 2 different hPSC clones were used for each condition in all experiments.
Reduced Efflux Capacity of ABCA1 −/− Macrophages
We confirmed the loss of ABCA1 protein expression in clones H11 and D6 by Western blot analysis ( Figure 2B ) in wholecell lysates from differentiated macrophages. The minimal residual ABCA1 expression observed in the knockout lysates may have resulted from cross-reaction with another protein or very low-percentage admixture of the cell lines with wildtype cells. There were no smaller protein products detected by the anti-ABCA1 antibody to suggest expression from alternative ABCA1 transcripts. Confirming that loss of ABCA1 had no effect on the efficacy of the differentiation protocol, both wild-type and ABCA1 −/− macrophages displayed similar levels of CD14, CD68, and CD163 expression ( Figure I macrophages had significantly reduced cholesterol efflux ability in comparison with isogenic wild-type macrophages that were differentiated in parallel ( Figure 2C ). ABCA1 −/− macrophages also demonstrated higher production of interleukin-1β and higher expression of proinflammatory genes, including IL1B, IL8, and CCL5 in response to lipopolysaccharide stimulation ( Figure 2D and 2E).
Discussion
In this report, we outline a successful strategy for creation of a human cell-based assay for macrophage RCT. We found that hPSC-derived macrophages display effective cholesterol efflux, and we propose that these cells can be used to systematically interrogate the role of human genetic variation in this pathway. As a proof of principle, we used CRISPR/ Cas9 genome editing to effect the loss of ABCA1 expression in differentiated macrophages. The macrophage RCT assay is designed to quantify the rate of cholesterol efflux from cultured cells to a plasma acceptor such as apoA1. 13 It has been used to measure cholesterol efflux in murine monocytes, 14 primary human monocytes, 13 and the acute monocytic leukemia cell line THP-1. 15 With this assay, our genome-edited ABCA1 −/− macrophages demonstrated reduced cholesterol efflux.
A role for ABCA1 in inflammation has been demonstrated in peritoneal macrophages isolated from macrophage-specific Abca1 −/− mice 16 but has not been confirmed with primary human macrophages because of difficulty in obtaining cells from patients with Tangier disease. In a recent report, iPSCderived macrophages from patients with Tangier disease displayed a proinflammatory signature when compared with iPSC-derived macrophages from control individuals. 8 The use of isogenic cell lines to study genetic alterations eliminates the clone-to-clone variability and effects of differences in genetic background often observed when studying iPSC lines derived from patients and control individuals. 17 We found with our genome-edited ABCA1 −/− macrophages that loss of ABCA1 indeed results in increased expression of proinflammatory cytokines.
The ability to readily genome-edit wild-type hPSC lines allows for testing of mutations without the need for identifying patients with mutations, obtaining primary tissues from those patients, and generating iPSC lines. This may prove to be useful in characterizing novel ABCA1 variants of unknown functional significance that are uncovered in next-generation sequencing studies of large human cohorts. Furthermore, genome-edited, hPSC-derived macrophages could allow for the interrogation of candidate RCT genes via gene knockout or even for unbiased screens. Thus, the approach presented here provides a human-based model with which to dissect RCT and potentially other aspects of macrophage biology. −/− macrophages display reduced cholesterol efflux to apoAI acceptor (calculated as the difference in efflux in the presence and absence of apoAI). Three biological replicates each of clones C10, C11, H11, and D6 were used; n=6 for each experimental condition. Error bars indicate SDs. D, ABCA1 −/− macrophages produce higher levels of IL-1β cytokine than wild-type macrophages after 18 h of stimulation with lipopolysaccharide (LPS). E, ABCA1 −/− macrophages display a larger degree of induction of proinflammatory cytokine mRNAs (relative to matched unstimulated macrophages) than WT macrophages after 18 h of LPS stimulation.
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